Cures matter, implementation counts too, aim high

James Burrus/NIST

Biomedical engineer Jenni Popp with NISTs prototype bioreactor for tissue engineering February 29, 2012.

Article Highlights

  • In our efforts to improve American medicine, we shouldn’t scale back on our fundamental ambitions. @DShaywitz.

    Tweet This

  • Even as we try to use available resources effectively, it’s key to develop & offer novel treatments that may work better.

    Tweet This

  • Bottom line: Biomedical science is difficult, fragile and essential. @DShaywitz

    Tweet This

In the online edition of today's Atlantic, I share a piece that distills several topics familiar to readers of this column.  I write that in our efforts to improve American medicine, we shouldn't scale back on our fundamental ambitions - specifically, our investment in high-tech medical science, and our belief that each patient deserves the best care possible.

I argue that it's incredibly important to ensure technological advances are accessible to patients, and actually benefit them; yet, in attempting to effect a more equitable distribution of health, let's be careful not to reduce either our drive or ability to maximize individual health. 

Phrased differently: even as we strive to use available resources as effectively as possible, we must continue to develop and offer patients novel treatments that might work even better.

Most importantly, we must ensure physician remain advocates for the individual patients in their care, and not ask doctors to balance care of an individual patient with a broader commitment to preserving resources for society.  I don't want my doctor to recommend unnecessary or unhelpful treatments, and I certainly wouldn't want to stay in any hospital for one nanosecond longer than medically necessary - yet I also want to be positively sure that my doctor's recommendations are based on an absolute commitment to optimize my health, and not on some gauzy ethical balancing act he or she is trying to achieve.  (See here, and links therein, for more complete discussion.)

In the Atlantic piece, I also discuss the increasing concern that modern high-tech medicine has overpromised and underdelivered.  While I'm proud of the many achievements of biomedical science, it's true that we've come up short in a number of areas - neurodegenerative disease and most cancers come immediately to mind.  Our scientific foundation is considerably more fragile than many appreciate (a fact definitely not lost on most biotech investors these days), and industry plays a vital role in pressure-testing this knowledge, unfortunately discovering in the process just how shaky it is.

Consequently, while it's fashionable to critique the business-oriented executives who run most biopharmaceutical companies - and I certainly have - it's also likely the industry owes its survival not only to the  valiant effort of scientists, but also to the executives in suits who've found a way to manage through the frequent productivity droughts, usually through shrewd business acumen (and occasionally, as recent scandals suggest, through unfortunate and obviously unacceptable means).

Bottom line: biomedical science is difficult, fragile, and essential - qualities that map directly to the current state and esteem of the biopharmaceutical industry.   It's also critically important to figure out how to best use the technologies we already have, and to significantly improve care delivery - a vital area of medical research that has historically suffered from significant underinvestment.  Our key challenge is ensuring that in our increasingly deliberate efforts to manage and improve the health of society as a whole, we not lose focus on doing our utmost to improve the present and future health of the individual patients in our trust and care.

Final note: CATCH (the Center for Assessment Technology and Continuous Health), the new (non-profit) Boston-based innovation initiative I recently co-founded with MGH Chief-of-Medicine Dennis Ausiello (who will lead the effort) and several others, seeks precisely this balance between potential and attained health.  The idea is that improved real-world measurement of people and patients can improve care delivery and implementation in the short-term, and lead to fundamental advances and novel scientific insights down the road (see here, here, and here.)


Also Visit
AEIdeas Blog The American Magazine
About the Author


  • Dr. Shaywitz trained in internal medicine and endocrinology at MGH, and conducted his post-doctoral research in the Melton lab at Harvard. He gained experience in early clinical drug development in the Department of Experimental Medicine at Merck, then joined the Boston Consulting Group’s Healthcare and Corporate Development practices, where he focused on strategy and organizational design. He is currently Director of Strategic and Commercial Planning at Theravance, a publicly-held drug development company in South San Francisco. He recently wrote Tech Tonics: Can Passionate Entreprenuers Heal Healthcare With Technology? 

  • Email:

What's new on AEI

image Recovering from tax time blues
image 10 welfare reform lessons
image Let HHS nominee Sylvia Burwell explain Obamacare lie
image Why bold ideas backfire in politics
AEI on Facebook
Events Calendar
  • 14
  • 15
  • 16
  • 17
  • 18
Wednesday, April 16, 2014 | 10:00 a.m. – 11:00 a.m.
Calling treason by its name: A conversation with Liam Fox

Join us at AEI as the Right Honorable Liam Fox sits down with Marc Thiessen to discuss and debate whether America’s intelligence agencies have infringed on the personal privacy of US citizens.

Thursday, April 17, 2014 | 4:00 p.m. – 5:00 p.m.
The curmudgeon's guide to getting ahead

How can young people succeed in workplaces dominated by curmudgeons who are judging their every move? At this AEI book event, bestselling author and social scientist Charles Murray will offer indispensable advice for navigating the workplace, getting ahead, and living a fulfilling life.

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.